Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

Article content

Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise

Article content

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (the “Company” or “Unbuzzd”), the company behind unbuzzd™—the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms—is pleased to announce that it has engaged MZ Digital, a global leader in online marketing, and Dealmaker, a leading online platform for raising capital, to raise up to US$5 million through a Regulation D 506(c) offering. This format of raising capital allows businesses to sell and issue securities to accredited investors without a cap on the amount raised.

Article content

Article content

Article content

John Duffy, CEO of Unbuzzd Wellness Inc., stated, “We are dedicated to offering scientifically backed unbuzzd to alcohol consumers who want to enjoy themselves, stay in control, and feel great the next day. Our collaboration with MZ Digital and utilizing the Dealmaker platform will help us raise the necessary capital to support our direct-to-consumer, distributor, and retail expansion plans, allowing us to reach more consumers more often.” Mr. Duffy has over twenty years of leadership experience in the beverage industry, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola.

Article content

Article content

Gerry David, Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, “This capital raise will give us the ability to continue to grow the company and expand sales, while positioning unbuzzd for a future initial public offering.”

Article content

About Quantum BioPharma Ltd.

Article content

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Article content

Article content

Article content

About Unbuzzd Wellness Inc.

Article content

Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.

Article content

Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration (“BAC”), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include: